drugset / Trial / NCT00082602
Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
Phase 3
Completed
83 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho-McNeil Neurologics, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.
Timeline
- Start
- 2004-05
- Primary completion
- —
- Completion
- 2005-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 16 mg | Oral |